| As of Tuesday's close, ONCY had 7 analyst targets pointing to a significant amount of upside potential.
In fact, with an average target of $6.25, ONCY could have over 500% potential upside from its closing valuation on Tuesday the 3rd.
MarketBeat reports further that Patrick R. Trucchio of H.C. Wainwright has given ONCY a $10 target representing a potential upside over 1,000% from Tuesday's close.
Could (Nasdaq: ONCY) be undervalued from current chart levels? -----
#2. ONCY Potential Catalyst - Updated Clinical Data Acts As Attention-Grabbing Information.
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR
Combination achieved encouraging median DOR of almost 17 months
Data establishes clear path in indication with no approved therapy
SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous cell anal carcinoma (“SCAC”), a setting with no U.S. Food and Drug Administration (“FDA”)-approved treatment options. Previous analysis from this cohort has focused on second-line or later SCAC patients.
Updated GOBLET Cohort 4 Third-Line Anal Cancer Data
As of the current data cut, four of 14 evaluable third-line patients receiving pelareorep and atezolizumab achieved objective responses, resulting in an objective response rate (“ORR”) of approximately 29%. These responses included two complete responses and two partial responses. The median duration of response (“DOR”) is approximately 17 months (67 weeks), indicating both depth and durability of clinical benefit in a heavily pretreated population.
Patients enrolled in this cohort had progressed following multiple prior systemic therapies and represent a highly refractory disease population. In historical third-line SCAC studies, objective response rates are typically approximately 10% or less, with limited durability. There are currently no FDA-approved therapies for patients with third-line anal cancer.
The observed response rate and emerging durability in GOBLET Cohort 4 compare favorably with historical outcomes and highlight the potential clinical relevance of pelareorep plus atezolizumab in this setting of significant unmet medical need.
“As we continue to analyze the Goblet data, we are finding important trends that are helping to shape our clinical development strategy,” said Jared Kelly, Chief Executive Officer of Oncolytics. “When you isolate to anal cancer patients with two prior lines of treatment and see a strong signal like this, it points the arrow in a direct line to a registration study in an indication where there are no FDA-approved therapies. We already had good data here, but looking closer, it becomes clearer that we can make an immediate impact on patients’ lives who have no options.”
In the second-line setting, pelareorep and atezolizumab achieved a 30% ORR, more than doubling the 13.8% ORR that was approved by the FDA for the current standard of care therapy. Additionally, the median duration of response is 15.5 months for pelareorep and atezolizumab compared to 9.5 months (link to the PR).
...
Read the full article here. -----
#3. ONCY Potential Catalyst - An IP And Patent Update Highlights The Potential Of Future Commercialization Efforts.
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
Track 1 manufacturing patent application and additional planned filings to potentially extend patent coverage beyond 2044
SAN DIEGO, January 08, 2026--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the status of its intellectual property ("IP") portfolio and ongoing efforts to extend patent protection for pelareorep as part of the company’s long-term value creation and development strategy.
In early Q3 2025, Oncolytics filed a Track 1 prioritized examination patent application with the United States Patent and Trademark Office ("USPTO") focused on manufacturing-related innovations for pelareorep. If granted, this patent application could result in granted claims with a potential term extending to 2044, significantly lengthening the commercial runway for pelareorep.
The company received initial written feedback from the USPTO in Q4 2025. Based on the Track 1 timeline, Oncolytics expects a final action in Q3 2026 regarding this manufacturing patent application.
In addition, Oncolytics plans to file one or more additional patent applications relating to the manufacture and method-of-use covering novel therapeutic uses of pelareorep. If allowed, this could provide potential IP protection beyond 2044.
"Extending our intellectual property runway is a core pillar of our strategy," said Jared Kelly, Chief Executive Officer of Oncolytics. "As pelareorep continues to demonstrate meaningful clinical activity across gastrointestinal cancers, it is critical that we protect the innovation behind both how the therapy is manufactured and how it is used. These efforts are designed to give pelareorep the best possible chance to impact patients’ lives—particularly those with very limited treatment options—while also increasing long-term value for our shareholders."
Oncolytics stated that it expects to continue pursuing additional IP opp's in 2026 as part of a comprehensive approach to supporting late-stage development, potential regulatory approvals, and future commercialization of pelareorep.
Read the full article here. -----
#4. ONCY Potential Catalyst - Promising Efficacy And Translational Data Fly Off The Page (Multi-Bn Dollar Colorectal Cancer Market).
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
33% ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin + FOLFIRI of 6-11%
Translational analysis shows pelareorep enhances KRAS-mutant–specific T-cell activity, providing mechanistic support for clinical responses
Data strengthen pelareorep’s potential to transform a multi–Bn dollar underserved colorectal cancer market
SAN DIEGO, December 16, 2025--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced clinical and translational findings supporting the development of pelareorep in second-line metastatic colorectal cancer ("mCRC"), specifically in patients with KRAS-mutant, microsatellite-stable ("MSS") disease. This represents one of the most difficult-to-treat and least responsive subgroups within colorectal cancer.
In a previously completed clinical study evaluating pelareorep in combination with standard-of-care therapy, 33% of KRAS-mutant MSS patients achieved an objective response, compared to the well-established historical objective response rate ("ORR") of approximately 6–11% for Avastin® (bevacizumab) + FOLFIRI in second-line mCRC. In that same study, patients receiving the pelareorep, bevacizumab, and FOLFIRI treatment regimen more than doubled progression-free survival and overall survival compared to those receiving bevacizumab and FOLFIRI (click here for the PR).
In addition to the clinical activity, a separate translational analysis of paired tumor biopsies revealed that treatment with pelareorep led to a notable increase in KRAS-mutant–specific T-cell populations, indicating that pelareorep may directly enhance anti-tumor immune recognition in this genetically defined subgroup. These findings provide strong biological support for pursuing pelareorep as a precision immunotherapy capable of addressing a patient population that rarely benefits from checkpoint inhibitors or other immunotherapies. A complete analysis of the translational data will be presented at an upcoming medical meeting.
"Colorectal cancer is the core of our emerging GI tumor platform strategy for pelareorep, with a projected total addressable market of $20Bn by 2033," said Jared Kelly, Chief Executive Officer of Oncolytics Biotech. "Pelareorep has clearly demonstrated the potential to become a transformational new treatment option in this underserved setting. With translational data supporting its unique activation of KRAS-specific T cells, pelareorep has delivered a 33 percent response rate in KRAS-mutant, MSS colorectal cancer."
...
Read the full article here. -----
#5. ONCY Potential Catalyst - Two Recent Hires Stack The Team With Serious Experience.
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics
Appointments strengthen late-stage clinical execution and statistical leadership as the Company advances multiple registration-directed programs in gastrointestinal cancers
SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics. These appointments are expected to enhance the Company’s operational, clinical, and regulatory capabilities as Oncolytics advances registration-directed development programs in pancreatic, colorectal, and anal cancers.
Mr. McAdory will oversee clinical development execution, operational strategy, and regulatory readiness across the Company’s portfolio. He brings extensive experience leading late-stage oncology programs, particularly in the oncolytic vi-rus space. Most recently, Mr. McAdory served as Vice President, Clinical Operations at CG Oncology, Inc. (Nasdaq: CGON), a late-stage biotechnology company developing an intratumoral oncolytic virus. Over his career, he has managed large, registration-directed clinical trials involving hundreds of patients across multiple tumor types and supported global regulatory interactions.
“John’s background running complex, late-stage oncology trials makes him exceptionally well-suited to lead Oncolytics’ next phase of execution,” said Jared Kelly, Chief Executive Officer of Oncolytics. “As we progress toward pivotal and registration-enabling studies in anal, pancreatic, and colorectal cancers, his experience will be critical to ensuring disciplined execution, speed, and regulatory alignment.”
Mr. Wu joins Oncolytics to lead Biostatistics, bringing deep expertise in statistical strategy, regulatory interactions, and late-stage trial design. Most recently, he served as Head of Biostatistics at Morphic Therapeutic, where he supported multiple clinical programs through late-stage development and played a key role during the company’s acquisition by Eli Lilly and Company. Previously, Mr. Wu led statistical strategy and regulatory execution for multiple Phase 3 and registration oncology programs at Takeda, Pharmaceutical Company Limited (NYSE: TAK), leveraging innovative trial designs to accelerate late-stage development and global regulatory approvals.
“Yujun’s experience designing and supporting late-stage studies and interacting with regulators significantly strengthens our internal capabilities,” added Mr. Kelly. “As we pursue accelerated approval strategies and pivotal trials, high-quality statistical leadership is essential, and Yujun brings that expertise at a critical time for the Company.”
...
Read the full article here. -----
(Nasdaq: ONCY) Recap - 5 Potential Catalysts Hits Our Radar
#1. An Average Of 7 Analyst Targets Suggest Major Upside Potential (Triple-Digit!).
#2. Updated Clinical Data Acts As Attention-Grabbing Information.
#3. An IP And Patent Update Highlights The Potential Of Future Commercialization Efforts.
#4. Promising Efficacy And Translational Data Fly Off The Page (Multi-Bn Dollar Colorectal Cancer Market).
#5. Two Recent Hires Stack The Team With Serious Experience. -----
We're initiating coverage on Oncolytics Biotech Inc. (Nasdaq: ONCY).
Be on the lookout for updates coming your way soon. Talk shortly.
Sincerely, Kai Parker StockWireNews
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 02/03/2026 and ending on 02/04/2026 to publicly disseminate information about (ONCY:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). These Funds were part of the ninety thousand USD funds that TD Media LLC received from Oncolytics Biotech Inc., the issuer of (ONCY:US).
Neither SWN Media LLC, TD Media LLC and their member own shares of (ONCY:US).
Please see important disclosure information here: https://stockwirenews.com/disclosure/oncy-wayo3/#details | 
Tidak ada komentar:
Posting Komentar